Taylor Morrison Home
TMHC
Meritage Homes
MTH
D.R. Horton
DHI
Lennar Corp
LEN
Toll Brothers
TOL
US Stock MarketDetailed Quotes
NBIX Neurocrine Biosciences
- 115.900
- -3.210-2.69%
Close Feb 25 16:00 ET
- 115.900
- 0.0000.00%
Post 20:01 ET
11.56BMarket Cap35.23P/E (TTM)
120.000High115.200Low1.57MVolume118.600Open119.110Pre Close182.79MTurnover1.59%Turnover Ratio35.23P/E (Static)99.70MShares157.98052wk High4.46P/B11.42BFloat Cap110.95052wk Low--Dividend TTM98.52MShs Float157.980Historical High--Div YieldTTM4.03%Amplitude1.940Historical Low116.503Avg Price1Lot Size
About Neurocrine Biosciences Company
Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company, which engages in the research, development, and commercialization of pharmaceuticals for the treatment of neurological, neuroendocrine, and neuropsychiatric disorders. The company was founded by Kevin C. Gorman and Wylie W. Vale in January 1992 and is headquartered in San Diego, CA.
Company Profile
SymbolNBIX
Company NameNeurocrine Biosciences
Listing DateMay 23, 1996
Issue Price10.50
Founded1992
CEODr. Kyle W. Gano, PhD
MarketNASDAQ
Employees1800
Fiscal Year Ends12-31
Address6027 Edgewood Bend Court
CitySan Diego
ProvinceCalifornia
CountryUnited States of America
Zip Code92130
Phone1-858-617-7600
Websitehttp://www.neurocrine.com
Company Executives
- Name
- Position
- Salary
- Dr. Kyle W. Gano, PhD
- Director, Chief Executive Officer, President, Chief Business Development and Chief Strategy Officer
- 5.99M
- Dr. Jude Onyia, PhD
- Chief Scientific Officer
- 7.22M
- Julie S. Cooke
- Chief Human Resources Officer
- --
- Ingrid Delaet
- Chief Regulatory Officer
- --
- Eric S. Benevich
- Chief Commercial Officer
- --
- Darin M. Lippoldt
- Chief Legal Officer and Corporate Secretary
- --
- Matthew C. Abernethy
- Chief Financial Officer and Principal Accounting Officer
- 6.06M
- David W. Boyer
- Chief Corporate Affairs Officer
- --
- Dr. Eiry W. Roberts, M.D.
- Chief Medical Officer
- 5.87M
- Dr. William H. Rastetter,PhD
- Chairman of the Board
- 495.04K
- Dr. Kevin C. Gorman,PhD
- Director
- 15.75M
- George J. Morrow
- Independent Director
- 479.54K
- Richard F. Pops
- Independent Director
- 492.04K
- Gary A. Lyons
- Independent Director
- 460.11K
- Dr. Stephen A. Sherwin, M.D.
- Independent Director
- 479.54K
- Johanna Mercier
- Independent Director
- 467.61K
- Christine A. Poon
- Independent Director
- 813.45K
- Shalini Sharp
- Independent Director
- 497.11K
- Leslie V. Norwalk, Esq.
- Independent Director
- 475.11K
Trending Stocks
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.